India's Pharma Powerhouse: Exports Surge, Targeting US$ 50 Billion as Nation Transitions to High-Value 'Pharmacy of the World'

India's Pharma Powerhouse: Exports Surge, Targeting US$ 50 Billion as Nation Transitions to High-Value 'Pharmacy of the World'​

Record Growth Propels Indian Pharmaceutical Sector​

The Department of Commerce organized a major outreach programme at Pharmexcil’s Regional Office in Mumbai. The event highlighted the significant achievements and reforms implemented by the government over the past twelve years within India's pharmaceutical industry. Industry representatives from leading associations, including the Indian Drug Manufacturers' Association and the International Pharmaceutical Excipients Council, attended the session.

Shri Mohit Yadav, Joint Secretary of the Department of Commerce, addressed the participants during a media interaction. He underscored India's strong export trajectory and the deepening trade relations established with crucial international partners. The government is working closely with industry stakeholders to strengthen capabilities, aiming for a transition from volume-led exports to value-led growth.

Economic Milestones: From US$ 20 Billion to Global Leadership​

The Indian pharmaceutical sector has been recognized as a strategic national asset and a source of widespread pride. India now holds the reputation as the "Pharmacy of the World," built on commitments to quality, affordability, and reliable supply chains. The market scale has dramatically increased from approximately US$ 20 billion in 2014 to nearly US$ 60 billion by 2026.

Pharmaceutical exports alone have grown substantially. They moved from US$ 14 billion in FY 2015 to about US$ 31 billion in FY 2026, achieving a compound annual growth rate of 7.4 percent. The sector maintains an ambition to reach US$ 50 billion in exports by 2030.

Quality and Affordability Define India's Market Strength​

Affordability remains a defining strength for the Indian pharma industry globally. Indian generic medicines are instrumental in providing access to necessary treatments for millions worldwide. The country stands as the third largest producer of pharmaceuticals by volume, supplying around 20 percent of the global demand for generics.

Furthermore, the sector boasts a vast international reach. India exports pharmaceutical products to more than 200 countries. More than 60 percent of these exports are destined for strictly regulated international markets, demonstrating adherence to high standards. The government affirms that quality and continuity of supply are assured through its robust regulatory footprint, which includes approximately 1,000 US FDA-registered sites.

Strategic Initiatives Boost High-Value Manufacturing​

To solidify its global standing, the Department highlighted several major initiatives. Biopharma SHAKTI, or Strategy for Healthcare Advancement through Knowledge, Technology and Innovation, has been proposed with an outlay of ₹10,000 crore over five years. This initiative aims to position India as a global hub for biopharmaceutical manufacturing.

The program also noted the establishment of Global Capability Centres (GCCs) by multinational pharmaceutical companies within India. These centers currently employ more than 100,000 professionals and have attracted investments exceeding US$ 1 billion. GCCs support crucial functions like clinical operations, regulatory science, and digital health analytics.

Shifting Focus to Value-Added Drugs and Global Trade​

The next phase of growth for the pharmaceutical sector is explicitly defined by its shift from volume generation to value creation. While generics will remain the foundation, future expansion is set to be driven by advanced fields such as biosimilars, gene therapies, specialty medicines, and complex generics.

India’s trade agreements are poised to unlock new opportunities across key international markets. Engagements with partners like the European Union, Australia, the United Kingdom, and the Sultanate of Oman will support market access and regulatory cooperation. The India-EFTA Trade and Economic Partnership Agreement offers further possibilities in life sciences, backed by a commitment of US$ 100 billion investment over 15 years.